Israel - English - Ministry of Health

medison pharma ltd - pasireotide as pamoate - powder and solvent for suspension for injection - pasireotide as pamoate 10 mg/vial - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as pamoate - powder and solvent for suspension for injection - pasireotide as pamoate 30 mg/vial - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 20mg - pasireotide (pasireotide pamoate) 20mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 60mg - pasireotide (pasireotide pamoate) 60mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 40mg - pasireotide (pasireotide pamoate) 40mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 10mg - pasireotide (pasireotide pamoate) 10mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 30mg - pasireotide (pasireotide pamoate) 30mg - somatostatin agonists

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 20 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 40 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 60 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.